Skip to main content

Mutation-tracking blood test offers early detection of breast cancer relapse

Mutation-tracking’ blood test could predict breast cancer relapse
Scientists from the UK’s Institute of Cancer Research (ICR), London and The Royal Marsden NHS Foundation Trust have created a DNA-based blood test that can determine whether a breast cancer patient is at risk for relapse. The test can detect a recurrence several months before any other physical signs are evident, potentially making it useful as an early warning tool for these who have completed breast cancer treatment.

The blood test is engineered to detect minute quantities of tumor DNA in a patient’s bloodstream. This DNA emanates from the original tumor and is often left behind following cancer treatment. Each patient’s cancer cells are collected and the test is tailor-made to detect these unique tumor cells. These leftover cancer cells are critical to identify as they may eventually form new tumors and lead to a recurrence of breast and other cancers in patients.

Related Videos

blood testIn a study published in Science Translational Medicine, researchers collected blood samples from 55 women who were diagnosed with for early-stage breast cancer and successfully completed treatment for the disease. The research shows that patients with a detectable level of circulating tumor DNA were 12 times more likely to experience a relapse than those who tested negative for the cancer-originating DNA. The blood test also was able to predict a recurrence up to eight months before any physical signs of the cancer appeared.

The method is beneficial to physicians and patients alike as it utilizes a routine, non-invasive blood test that can safely repeated based on an individual patient’s treatment plan. It also avoids more expensive and invasive procedures such as mammograms, CAT scans, and biopsies. Given these advantages, the test will potentially make it easy for physicians to monitor breast cancer patients following treatment and provide early intervention if the risk of recurrence begins to climb.

Because of its early detection capability, researchers hope this blood test will “make a real difference to breast cancer patients,” but it is still in the early stage of development. Before it can be considered as an important diagnostic test, researchers need to expand their trials so they examine more closely whether the early detection provided by the test will lead to a positive outcome for patients.

Editors' Recommendations

Fitbit could be looking to get into the blood sugar tracking game
Fitbit Ionic

Six months after defeating rival Jawbone, Fitbit is looking to get in the ring with another competitor. The wearables company has just invested for the first time in a start-up, dedicating more than $6 million into a company called Sano, which is creating a small patch to track blood sugar levels for diabetics. This could help Fitbit compete more directly with Apple and its Apple Watch -- the Cupertino company is currently working on an in-house version of a noninvasive glucose monitor.

As per estimates from the Centers for Disease Control and Prevention. more than 100 million people in the United States are living with diabetes or pre-diabetes. As such, adding blood-sugar tracking functionality into a smart watch certainly seems like a strategic move. Indeed, both the Food and Drug Administration (FDA) and Apple seem to be heading towards a future where wearables are closer to medical devices than glorified digital watches -- recently, the FDA approved the first-ever medical device accessory for the Apple Watch, while Apple is reportedly looking to make its Watch into an EKG.

Read more
Test your blood from the comfort of your home with Athelas
apple diabetes research blood sugar check

Blood testing startup Theranos may be dead in the water, but that doesn't mean that the concept behind the disgraced startup has disappeared. Really, it has just found a new champion. Meet Athelas, heralded as an instant blood diagnostics system capable of testing for diseases such as the flu, bacterial infections, and even cancer. Best of all? You can do all your testing from the comfort of your own home.

Founded by Tanay Tandon when he was just 17, the three-year-old startup was initially intended to detect malaria via blood samples. But now, Tandon has expanded Athelas' capabilities. The cylindrical device (which looks a bit like an Amazon Echo) allows you to insert a slide with a few drops of your blood, and then determines whether your white blood cell count is abnormal. Your results are delivered to you via a companion app, and should be viewable within 60 seconds.

Read more
Hyperloop One transport system speeds forward with first test on full-scale track
hyperloop one

There may be those who continue to raise an eyebrow or two at the idea of the Hyperloop One becoming a reality, but at least one of the companies behind the super-fast transportation system is intent on seeing the project through to completion.

Just a few weeks after Hyperloop One announced the first successful test of a full-scale version of its technology in a vacuum environment, the company has made an even more significant leap forward. On July 29, Hyperloop One completed a test on its full-scale test track in Nevada, with the Hyperloop pod traversing almost the entirety of the 1640-foot-long structure. The vehicle hit speeds of up to 192 miles per hour during the test, setting a new record for Hyperloop test speeds.

Read more